Injection of Ranibizumab Versus Combination of Ranibizumab and Triamcinolone Acetate for (CRVO)

Assiut University100 enrolled

Overview

To compare the clinical effectiveness of ranibizumab and combination of ranibizumab and triamcinolone for the treatment of macular oedema secondary to CRVO

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

QUADRUPLE

Enrollment

100

Conditions

Ophthalmopathy

Interventions

RanibizumabDRUG

Intravitreal

RanibizumabDRUG

Intravitreal

triamcinolone acetateDRUG

intravitreal

Eligibility

Sex: ALLMin age: 18 YearsMax age: 70 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * Patients 18 years of age or older with visual impairment resulting from macular edema secondary to CRVO. * A BCVA approximate Snellen equivalents, 20/40. Exclusion Criteria: * Use of intra-vitreal anti-VEGF injections 3 months or less before baseline. * Pan-retinal laser photocoagulation 3 months or less before baseline, * Topical ocular or systemic corticosteroids administered for 30 consecutive days. * Intraocular or periocular corticosteroid use 3 months or less before screening (study eye), * Use of intraocular corticosteroid implants, * Uncontrolled glaucoma (intraocular pressure \[IOP\] 30 mmHg with medication) at the time of screening or baseline, * iris neovascularization or neo-vascular glaucoma.

Locations (1)

Wael

Asyut, Egypt

RECRUITING

Outcomes

Primary Outcomes

Comparison between intravitreal injection of ranibizumab and combination of ranibizumab and triamcinolone acetate for the treatment of macular edema secondary to CRVO

Time frame: 2 year

Comparison between intravitreal injection of ranibizumab and combination of ranibizumab and triamcinolone acetate for the treatment of macular edema secondary to CRVO

To compare the clinical effectiveness of 0.5 mg ranibizumab and combination of ranibizumab and triamcinolone 0.3/0.5mg for the treatment of macular oedema secondary to CRVO.Study assessments will be performed at screening, baseline and at monthly visits: Optical Coherence Tomography: will be performed at every visit and the same machine will be used for assessment of the same patient throughout the study. investigator will evaluate the images according to central foveal thickness, and the retinal thickness at the foveal center point and to capture the presence or absence of qualitative parameters (i.e., intraretinal cystoid fluid and subretinal fluid).

Time frame: 2 year

Central Contacts

Wael Ismael

CONTACT

01006322380 wael.ali.ismael@gmail.com

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.